


Product overview

The Tack endovascular system is a first-of-its-kind focal stent implant that is purpose-built to provide precision treatment of peripheral arterial dissections following balloon angioplasty in either above- or below-the-knee therapeutic interventions.

Product highlights

The Tack implant features **adaptive sizing** which allows the device to adapt to tapering anatomy while maintaining a relatively constant radial force, so that a single Tack implant can be used across a range of vessel diameters.

- 4F/.014" and 6F/.035" OTW delivery systems
- 135 and 150 cm working lengths
- Four or six pre-loaded Tack implants
- Self-sizes to tapering vessel diameters from 1.5-4.5 mm, 2.5-6.0 mm, and 4.0-8.0 mm with a single system
- Accurate (≤ 1 mm) deployment
- Nitinol with gold radiopaque markers



Tack (4F) implant
1.5-4.5 mm

Tack (6F) implant
2.5-6.0 mm


Tack (6F) implant
4.0-8.0 mm

Tack endovascular system (6F)

SKU #	Catheter length (cm)	Implant length (mm)	Number of Tack implants	Treatment range (mm)
156135062	135	6.0	6	2.5-6.0
206135062	135	8.0	6	4.0-8.0

Tack endovascular system (4F)

SKU #	Catheter length (cm)	Implant length (mm)	Number of Tack implants	Treatment range (mm)
154150042	150	6.0	4	1.5-4.5



Tack (4F) implant

Intended use: The Tack endovascular system (6F, 3.5-6.0 mm US/ 2.5-6.0 mm EU and 4.0-8.0 mm) is intended for use in the superficial femoral and proximal popliteal arteries ranging in diameter from 3.5 mm to 6.0 mm US/ 2.5 to 6.0 mm EU and 4.0 mm to 8.0 mm for the repair of post percutaneous transluminal balloon angioplasty (PTA) dissection(s).

The Tack endovascular system (4F, 1.5-4.5 mm) is intended for use in mid/distal popliteal, tibial and peroneal arteries, ranging in diameter from 1.5 mm to 4.5 mm, for the repair of post percutaneous transluminal balloon angioplasty (PTA) dissection(s).

Contraindications for use: The Tack endovascular system is contraindicated for the following: 1. Patients with residual stenosis in the treated segment equal to or greater than 30% after PTA. 2. Tortuous vascular anatomy significant enough to prevent safe introduction and passage of the device. 3. Patients with a known hypersensitivity to nickel-titanium alloy (Nitinol). 4. Patients unable to receive standard medication used for interventional procedures such as anticoagulants, contrast agents and antiplatelet therapy.

Prior to using the Tack endovascular system, please review the instructions for use for a complete listing of indications, contraindications, warnings, precautions, potential adverse events and directions for use.

Tack endovascular system is CE Mark authorized under EC directive 93/42/EEC. Tack endovascular system and Tack are registered trademarks of Intact Vascular, Inc. Adaptive sizing is a trademark of Intact Vascular, Inc.

